Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1995-06-05
1997-04-29
Rollins, John W.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
435431, A61K 3578, C12N 500
Patent
active
056246722
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to compositions of matter which are effective in inhibiting apoptotic cell death.
BACKGROUND OF THE INVENTION
Apoptosis is a normal physiologic process that leads to individual cell death. This process of programmed cell death is involved in a variety of normal and pathogenic biological events and can be induced by a number of unrelated stimuli. Changes in the biological regulation of apoptosis also occur during aging and are responsible for many of the conditions and diseases related to aging. Recent studies of apoptosis have implied that a common metabolic pathway leading to cell death may be initiated by a wide variety of signals, including hormones, serum growth factor deprivation, chemotherapeutic agents, ionizing radiation, and infection by human immunodeficiency virus (HIV). Wyllie (1980) Nature 284:555-556; Kanter et al. (1984) Biochem. Biophys. Res. Commun. 118:392-399; Duke and Cohen (1986) Lymphokine Res. 5:289-299; Tomei et al. (1988) Biochem. Biophys. Res. Commun. 155:324-331; and Kruman et al. (1991) J. Cell. Physiol. 148:267-273; Ameisen and Capron (1991) Immunol. Today 12:102-105; and Sheppard and Ascher (1992) J. AIDS 5:143-147. Agents that affect the biological control of apoptosis thus have therapeutic utility in numerous clinical indications.
Apoptotic cell death is characterized by cellular shrinkage, chromatin condensation, cytoplasmic blebbing, increased membrane permeability and internucleosomal DNA cleavage. Gerschenson et al. (1992) FASEB J. 6:2450-2455; and Cohen and Duke (1992) Ann. Rev. Immunol. 10:267-293.
All references cited herein both supra and infra are hereby incorporated herein by reference.
A variety of food supplements containing, in part, partially processed plant extracts have been used to ameliorate the gastrointestinal disorders that often accompany chemotherapy, radiation and AIDS. The supplements generally contain carbohydrates, fat and plant protein hydrolysates. See, e.g., Tomei and Cope et al. in Apoptosis The Molecular Basis of Cell Death (1991) Cold Spring Harbor Laboratory Press.
Several proteinase inhibitors derived from plant extracts have anticarcinogenic activity. Troll et al. (1987) Adv. Cancer Res. 49:265-283. The Bowman-Birk inhibitors are the best described of these inhibitors. Birk (1985) Int. J. Pep. Pro. Res. 25:113-131. Bowman-Birk inhibitors are described as a family of disulfide bonded proteins with a molecular weight of about 8 kD which suppress cellular transformation. Chou et al. (1974) Proc. Natl. Acad. Sci. USA 71:1748-1752; Yavelow et al. (1985) Proc. Natl. Acad. Sci. USA 82:5395-5399; and Yavelow et al. (1983) Cancer Res. (Suppl.) 43:2454s-2459s. Crude soybean extracts containing Bowman-Birk inhibitors have been described. Kennedy et al. U.S. Pat. No. 4,793,996; PCT publication No. WO 94/20121; and Kennedy, A. R. (1994) Cancer Res. (Suppl) 54:1999s-2005s. Bowman-Birk inhibitors have also been described immunologically. WO 90/03574; and U.S. Pat. Nos. 4,959,310; and 5,053,327. Bowman-Birk inhibitors have also been found to have activity in degranulation of macrophages. Japanese Patent No. 63-51335.
Lysophosphatidic acid (LPA) is found in a variety of plant products as are a variety of phospholipids. LPA has been found to have a variety of physiological activities including mitogenesis, growth factor and as an anti-wrinkle agent. U.S. Pat. Nos. 4,263,286; 4,746,652; 5,326,690; and 5,340,568. LPA is reviewed in detail by Moolenaar (1994) TICB 4:213-219; and Eichholtz et al. (1990) Biochem. J. 291:677-680.
SUMMARY OF THE INVENTION
The present invention encompasses methods of obtaining compositions that inhibit apoptosis and the compositions obtained thereby. The compositions are termed phytogenic apoptosis inhibitors (PAIs). The invention encompasses physiologically acceptable compositions suitable for administering the PAIs in an amount sufficient to modulate apoptosis. The invention further encompasses methods of use of the PAIs.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 presents the
REFERENCES:
patent: 4263286 (1981-04-01), Nakajima et al.
patent: 4340586 (1982-07-01), Bekierkunst et al.
patent: 4695590 (1987-09-01), Lippman
patent: 4746652 (1988-05-01), Buckalew, Jr. et al.
patent: 4793996 (1988-12-01), Kennedy et al.
patent: 4818540 (1989-04-01), Chien et al.
patent: 4959310 (1990-09-01), Brandon et al.
patent: 4959353 (1990-09-01), Brown et al.
patent: 5053327 (1991-10-01), Brandon et al.
patent: 5093505 (1992-03-01), Nishino et al.
patent: 5130298 (1992-07-01), Cini et al.
patent: 5140043 (1992-08-01), Darr et al.
patent: 5217717 (1993-06-01), Kennedy et al.
patent: 5326690 (1994-07-01), Xu et al.
patent: 5340568 (1994-08-01), Piazza et al.
Wyllie, "Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation" Nature (1980) 284:555-556.
Kanter et al., "Epidermal growth factor and tumor promoters prevent DNA fragmentation by different mechanisms" Biochem. Biophys. Res. Commun. (1984) 118(12):392-399.
Duke et al., "IL-2 addiction: Withdrawal of growth factor activates a suicide program in dependent T cells" Lymphokine Res. (1986) 5(4):289-299.
Tomei et al., "Inhibition of radiation-induced apoptosis in vitro by tumor promoters" Biochem. Biophys. Res. Commun. (1988) 155(1):324-331.
Kruman et al., "Apoptosis of murine BW 5147 thymoma cells induced by dexamethasone and .gamma.-irradiation" J. Cell. Physiol. (1991) 148:267-273.
Ameisen et al., "Cell dysfunction and depletion in AIDS: The Programmed cell death hypothesis" Immunol. Today (1991) 12(4):102-105.
Sheppard et al., "The relationship between AIDS and immunologic tolerance" J. AIDS (1992) 5:143-147.
Gerschenson et al., "Apoptosis: A different type of cell death" FASEB J. (1992) 6:2450-2455.
Cohen et al., "Apoptosis and programmed cell death in immunity" Annu. Rev. Immunol. (1992) 10:267-293.
Tomei et al., eds., Apoptosis: The Molecular Basis of Cell Death (1991) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. The title page and table of contents were previously submitted.
Troll et al., "Anticarcinogenic action of protease inhibitors" Adv. Cancer Res. (1987) 49:265-283.
Birk, "The Bowman-Birk inhibitor" Int. J. Peptide Protein Res. (1985) 25:113-131.
Chou et al., "Non-selective inhibition of transformed cell growth by a protease inhibitor" Proc. Natl. Acad. Sci. USA (1974) 71(5):1748-1752.
Yavelow et al., "Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro" Proc. Natl. Acad. Sci. USA (1985) 82:5395-5399.
Yavelow et al., "Bowman-Birk soybean protease inhibitor as an anticarcinogen" Cancer Res. (1983) 43:2454z-2459s.
Bligh et al., "A rapid method of total lipid extraction and purification" Can. J. Biochem. Physiol. (1959) 37(8):911-917.
Patton et al., "Separation of phospholipids and individual molecular species of phospholipids by high-performance liquid chromatography" J. Lipid Res. (1982) 23:190-196.
Takasaki et al., "Hydrazinolysis of asparagine-linked sugar chains to produce free oligosaccharides" Meth. Enzymol. (1982) 83:263-268.
Dawson et al., eds., Data for Biochemical Research (1986) 3rd ed., Clarendon Press, Oxford. A title page and table of contents were previously submitted.
Simpson, "Stimulation of hypertrophy of cultured neonatal rat heart cells through an .alpha..sub.1 -adrenergic receptor and induction of beating through an .alpha..sub.1 -and .beta..sub.1 -adrenergic receptor interaction" Cir. Res. (1985) 56(6):884-894.
Hardy et al., "High-pH anion-exchange chromatography of glycoprotein-derived carbohydrates" Meth. Enzymol. (1994) 230:208-225.
Sojar et al., "Chemical deglycosylation of glycoproteins" Meth. Enzymol. (1987) 138:341-350.
Funk et al., "Effect of soy products on methotrexate toxicity in rats" J. Nutr. (1991) 121:1684-1692.
Funk et al., "Effect of fiber, protein source and time of feeding on methotrexate toxicity in rats" J. Nutr. (1991) 121:1673-1683.
Sambrook et al., eds., Molecular Cloning. A Laboratory Manual (1989) 2nd. ed., Vol. 1-3,
Barr Philip J.
Bathurst Ian C.
Bradley John D.
Tomei L. David
LXR Biotechnology Inc.
Rollins John W.
LandOfFree
Compositions which inhibit apoptosis, methods of purifying the c does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions which inhibit apoptosis, methods of purifying the c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions which inhibit apoptosis, methods of purifying the c will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703987